Is there any new update related to alzeimers
Reading File
Reading File
Finding Sources
Searching PubMed
"Alzheimer Disease"[MeSH Terms]
Searching the Web
Alzheimer's disease latest updates 2026 treatments diagnosis research FDA
Quick answer
Yes. The biggest 2026 Alzheimer’s updates are in earlier diagnosis, easier treatment delivery, and symptom control:
-
Blood tests: The FDA has cleared additional blood-based tests, including Roche’s Elecsys pTau217 assay, to help assess Alzheimer-related amyloid pathology in people with cognitive symptoms. These tests support evaluation but do not replace a clinician’s full assessment. Alzheimer’s Association update
-
Leqembi (lecanemab): A subcutaneous starter-dose option was approved, expanding a treatment already used for early Alzheimer’s disease. Anti-amyloid drugs can slow decline modestly in selected patients, but require confirmation of amyloid and safety monitoring, particularly for ARIA brain swelling or bleeding seen on MRI. Leqembi update
-
Agitation treatment: Auvelity (dextromethorphan-bupropion, AXS-05) has been approved in the US for agitation associated with Alzheimer’s disease, adding an option for a distressing behavioral symptom. Non-drug approaches such as predictable routines and environmental changes remain first-line where feasible. Approval announcement
-
Tau PET imaging: The FDA approved florquinitau F 18 (Tauklarify) for PET imaging to identify tau neurofibrillary-tangle pathology in adults being evaluated for Alzheimer’s disease. FDA approval list
-
Research pipeline: Trials are increasingly targeting more than amyloid, including tau, inflammation, metabolism, synapses, and prevention in people who have biomarkers but no symptoms. Multiple phase 3 trials are expected to report during 2026. 2026 pipeline report
The key practical message: Alzheimer’s still has no cure, but diagnosis is becoming less invasive and there are more options to slow early disease or treat difficult symptoms. These therapies are not suitable for every person with memory loss, so evaluation by a memory specialist is important.
Is there any treatment options for alzheimers in india
Reading File
Finding Sources
Searching PubMed
"Alzheimer Disease"[MeSH Terms] AND India
Searching the Web
India Alzheimer disease treatment donepezil rivastigmine galantamine memantine lecanemab availability India 2026
Reading File
Searching the Web
site:cdsco.gov.in lecanemab OR donanemab OR Leqembi OR Kisunla India approval Alzheimer
Searching the Web
Alzheimer treatment guidelines India donepezil rivastigmine galantamine memantine availability India
Yes. In India, the established treatment options for Alzheimer’s disease are available by prescription, but they improve symptoms or function modestly and do not cure or reverse the disease.
Medicines for memory and daily functioning
| Stage / situation | Common options in India |
|---|---|
| Mild to moderate Alzheimer’s dementia | Donepezil, rivastigmine (capsule, liquid, or patch in some settings), or galantamine |
| Moderate to severe Alzheimer’s dementia | Memantine, often alongside a cholinesterase inhibitor such as donepezil |
| Moderate to severe disease | A fixed-dose donepezil + memantine combination may be used |
Indian dementia guidance follows this general approach. Donepezil is commonly prescribed, while rivastigmine or galantamine can be considered if it is not tolerated or suitable. A recent Indian multicentre prescribing study found donepezil and donepezil-memantine combinations were the most frequent treatments. Indian dementia study
Typical adverse effects require monitoring:
- Donepezil, rivastigmine, galantamine: nausea, vomiting, diarrhoea, reduced appetite/weight, dizziness, slow heart rate or fainting in susceptible people.
- Memantine: dizziness, headache, constipation, confusion in some people.
The usual indication pattern is cholinesterase inhibitors for mild to moderate disease, and memantine for moderate to severe disease. Donepezil can also be used later in the illness. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, p. 13056.
New anti-amyloid medicines
Drugs such as lecanemab (Leqembi) and donanemab (Kisunla) have been approved in some countries for selected people with early Alzheimer’s and confirmed brain amyloid. They can slow decline, but they need specialist selection, brain MRI monitoring, and management of ARIA, a risk of brain swelling or bleeding.
I could not confirm an Indian CDSCO approval or routine availability for lecanemab or donanemab from the official Indian results reviewed. They should therefore not be assumed to be routinely accessible in India. A neurologist at a cognitive or memory clinic can check current local availability, trial enrolment, and eligibility. In contrast, CDSCO records do show Indian approval history for donepezil products and donepezil-memantine combinations. CDSCO approval record
Treatment beyond medication
This is as important as tablets:
- Confirm that memory problems are truly Alzheimer’s, rather than depression, thyroid disease, vitamin B12 deficiency, medication effects, stroke-related dementia, or another condition.
- Treat hearing/vision issues, sleep disturbance, diabetes, hypertension, depression, pain, constipation, and infection.
- Maintain routine physical activity, safe social engagement, familiar activities, good sleep, nutrition, and caregiver support.
- Make the home safer: fall prevention, medication supervision, stove and driving assessment, and plans for wandering or getting lost.
- Agitation, hallucinations, insomnia, or aggression should first prompt a search for pain, delirium, infection, constipation, or environmental triggers. Sedative or antipsychotic medicines are sometimes used only when symptoms create serious distress or danger, and should be clinician-supervised.
Avoid relying on supplements, “memory tonics,” piracetam, or herbal products as Alzheimer’s treatment. Good evidence does not show that vitamin E, ginkgo biloba, or similar products treat dementia, and some can cause harm or interact with medicines. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, p. 13056.
A neurologist, geriatrician, or psychiatrist with dementia experience can tailor the choice based on disease stage, heart rhythm, body weight, kidney function, current drugs, and the person’s main symptoms.
This is a shared conversation. Sign in to Orris to start your own chat.